Novo Nordisk announced the filing of 14 new lawsuits to safeguard patients from unsafe and unapproved compounded weight loss drugs claiming to contain semaglutide. The lawsuits allege that telehealth providers violate state corporate practice of medicine laws by improperly influencing doctors' decisions and steering patients toward knockoff compounded semaglutide under the false guise of personalized medicine. 

Novo Nordisk has filed 132 lawsuits in federal courts across 40 states, resulting in 44 permanent injunctions to stop unsafe, illegal marketing and selling of knockoff Wegovy and Ozempic. Today's lawsuits build on Novo Nordisk's earlier litigation successes and expand the focus of its legal actions into two new areas:

• Pharmacies producing unapproved compounded "semaglutide" drugs under the fake guise of personalization in violation of state law.
• Telehealth companies where corporations, not doctors, improperly steer patient care to compounded "semaglutide" drugs using sham claims of personalization, violating California law.

Courts have already issued 44 permanent injunctions against defendants in similar cases, prohibiting them from a variety of alleged unlawful conduct including unlawfully compounding "semaglutide" and falsely claiming that compounded "semaglutide" products are FDA-approved, safe, or equivalent to Novo Nordisk's authentic medicines like Wegovy or Ozempic. Courts have also taken steps to deter similar conduct, including ordering defendants to forfeit illegally obtained profits.

Read more at Reuters >>